专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005111065A2 EPITOPE-ENHANCEMENT OF A HUMAN CD4 HIV EPITOPE 审中-公开
标题翻译：人类CD4 HIV外显子的抗体增强
公开(公告)号：WO2005111065A2
公开(公告)日：2005-11-24
申请号：PCT/US2005/014569
申请日：2005-04-27
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , BERZOFSKY, Jay, A. , OKAZAKI, Takahiro
发明人： BERZOFSKY, Jay, A. , OKAZAKI, Takahiro
IPC分类号： C07K14/155
CPC分类号： C07K14/005 , A61K2039/5154 , A61K2039/5158 , A61K2039/57 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322
摘要： Virus-specific CD4 + T cell help and CD8 + cytotoxic T cell responses are critical for the maintenance of effective immunity in chronic viral infections. The importance of the CD4 + T cells has been documented in HIV infection. A T1-specific CD4 + T cell line from a healthy volunteer immunized with a canarypox vector expressing gpl20 has been developed. The cell line was restricted to DR13, which is common in the U.S. in both Caucasians and African-Americans and is one of the major haplotypes in Africans. Amino acid substitutions in the T1 epitope were made to induce a stronger epitope-specific CD4 + T cell response than the original epitope resulting in an improved CD4 epitope. A polypeptide comprising the enhanced CD4 epitope can be used as a component in compositions either alone or in combination with other adjuvants and other immunogenic compositions to induce a more effective immune response to HIV infection.
摘要翻译：病毒特异性CD4 + T细胞帮助和CD8 +细胞毒性T细胞反应对于维持慢性病毒感染的有效免疫是至关重要的。 HIV感染中CD4 + T细胞的重要性已有记载。已经开发了用表达gp120的金丝细胞病毒载体免疫的健康志愿者的T1特异性CD4 + T细胞系。细胞系限于DR13，这是美国在高加索人和非洲裔美国人中常见的，是非洲人的主要单倍型之一。使T1表位中的氨基酸取代引起比原始表位更强的表位特异性CD4 + T细胞应答，从而导致改善的CD4表位。包含增强的CD4表位的多肽可以单独使用或与其它佐剂和其它免疫原性组合物组合用作组合物，以诱导对HIV感染的更有效的免疫应答。

2. 发明申请

WO2006091798A2 VACCINES AND METHODS FOR PREVENTION AND TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS 审中-公开
标题翻译：预防和治疗耐药性HIV-1和乙型肝炎病毒的疫苗和方法
公开(公告)号：WO2006091798A2
公开(公告)日：2006-08-31
申请号：PCT/US2006/006563
申请日：2006-02-22
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , CATANZARO, Andrew , YARCHOAN, Robert , BERZOFSKY, Jay A. , OKAZAKI, Takahiro , SNYDER, James, T., II , BRODER, Samuel
发明人： CATANZARO, Andrew , YARCHOAN, Robert , BERZOFSKY, Jay A. , OKAZAKI, Takahiro , SNYDER, James, T., II , BRODER, Samuel
IPC分类号： A61K39/21 , A61K39/29 , C07K14/02 , C07K14/16 , C07K14/18 , A61K39/12 , A61K31/00
CPC分类号： A61K39/00 , A61K2039/57 , C07K14/005 , C12N2710/16722 , C12N2730/10122 , C12N2740/16222 , C12N2770/24222
摘要： The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.
摘要翻译：本发明提供了通过诱导细胞毒性T淋巴细胞（CTL）来识别抗药性病毒的病毒蛋白质内的预定的突变表位来降低对抗病毒药物具有抗性的病毒的病毒载量的方法。通过用包含预定突变的肽免疫宿主诱导CTL。可以通过用于诱导特异性CTL的表位增强来进一步改善免疫刺激肽。由本发明组合物显示并由人HLA限制性CTL介导的抗药性病毒的抗病毒保护尚未获得。

3. 发明申请

WO2005111065A3 EPITOPE-ENHANCEMENT OF A HUMAN CD4 HIV EPITOPE 审中-公开
标题翻译：人类CD4 HIV外显子的抗体增强
公开(公告)号：WO2005111065A3
公开(公告)日：2006-03-30
申请号：PCT/US2005014569
申请日：2005-04-27
申请人： US GOV HEALTH & HUMAN SERV , BERZOFSKY JAY A , OKAZAKI TAKAHIRO
发明人： BERZOFSKY JAY A , OKAZAKI TAKAHIRO
IPC分类号： C07K14/16 , A61K39/21 , A61P31/18 , C07K14/155
CPC分类号： C07K14/005 , A61K2039/5154 , A61K2039/5158 , A61K2039/57 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322
摘要： Virus-specific CD4 + T cell help and CD8 + cytotoxic T cell responses are critical for the maintenance of effective immunity in chronic viral infections. The importance of the CD4 + T cells has been documented in HIV infection. A T1-specific CD4 + T cell line from a healthy volunteer immunized with a canarypox vector expressing gpl20 has been developed. The cell line was restricted to DR13, which is common in the U.S. in both Caucasians and African-Americans and is one of the major haplotypes in Africans. Amino acid substitutions in the T1 epitope were made to induce a stronger epitope-specific CD4 + T cell response than the original epitope resulting in an improved CD4 epitope. A polypeptide comprising the enhanced CD4 epitope can be used as a component in compositions either alone or in combination with other adjuvants and other immunogenic compositions to induce a more effective immune response to HIV infection.
摘要翻译：病毒特异性CD4 + T细胞帮助和CD8 +细胞毒性T细胞应答对于维持慢性病毒感染中的有效免疫是至关重要的。在HIV感染中已经记录了CD4 + T细胞的重要性。已经开发了用表达gp120的金丝细胞病毒载体免疫的健康志愿者的T1特异性CD4 + T细胞系。细胞系限于DR13，这是美国在高加索人和非洲裔美国人中常见的，是非洲人的主要单倍型之一。使得T1表位中的氨基酸取代引起比原始表位更强的表位特异性CD4 + T细胞应答，导致改善的CD4表位。包含增强的CD4表位的多肽可以单独使用或与其它佐剂和其它免疫原性组合物组合用作组合物，以诱导对HIV感染的更有效的免疫应答。

4. 发明申请

WO2004092201A3 ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE 审中-公开
标题翻译：增强的HIV-1疫苗及其使用方法
公开(公告)号：WO2004092201A3
公开(公告)日：2004-12-02
申请号：PCT/US2004009617
申请日：2004-03-29
申请人： US GOV HEALTH & HUMAN SERV , BERZOFSKY JAY A , OKAZAKI TAKAHIRO
发明人： BERZOFSKY JAY A , OKAZAKI TAKAHIRO
IPC分类号： A61K39/21 , A61K39/385 , C07K20060101 , C07K14/16
CPC分类号： C12N9/1276 , A61K39/00 , A61K39/12 , A61K39/21 , A61K39/385 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55522 , A61K2039/55566 , A61K2039/57 , A61K2039/6018 , A61K2039/645 , C07K14/005 , C12N7/00 , C12N2740/16222 , C12N2740/16234
摘要： ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE ABSTRACT The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.
摘要翻译：增强的HIV-1疫苗及其使用方法摘要本发明提供了用于第二代HIV疫苗的肽和蛋白质，并作为治疗和控制HIV感染的诊断工具。用本发明的组合物显示的抗病毒保护以前没有用HLA表位增强的疫苗实现。这些发现确定了有效表位增强所需的MHC亲和力与受体交叉反应性之间的关键平衡，并且还证明了新一代疫苗的这种组分的构建和功效。

5. 发明申请

WO2004092201A2 ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE 审中-公开
标题翻译：增强HIV-1疫苗及其使用方法
公开(公告)号：WO2004092201A2
公开(公告)日：2004-10-28
申请号：PCT/US2004/009617
申请日：2004-03-29
申请人： THE GOVERMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , BERZOFSKY, Jay, A. , OKAZAKI, Takahiro
发明人： BERZOFSKY, Jay, A. , OKAZAKI, Takahiro
IPC分类号： C07K
CPC分类号： C12N9/1276 , A61K39/00 , A61K39/12 , A61K39/21 , A61K39/385 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55522 , A61K2039/55566 , A61K2039/57 , A61K2039/6018 , A61K2039/645 , C07K14/005 , C12N7/00 , C12N2740/16222 , C12N2740/16234
摘要： ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE ABSTRACT The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.
摘要翻译：增强的HIV-1疫苗及其使用方法本发明提供用于第二代HIV疫苗的肽和蛋白质，以及用于治疗和控制HIV感染的诊断工具。本发明组合物显示的抗病毒保护尚未以HLA表位增强疫苗实现。这些发现定义了有效表位增强所需的MHC亲和力和受体交叉反应之间的关键平衡，并且还证明了新一代疫苗的这种组分的构建和功效。

6. 发明申请

WO2006091798A3 VACCINES AND METHODS FOR PREVENTION AND TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS 审中-公开
标题翻译：预防和治疗耐药性HIV-1和乙型肝炎病毒的疫苗和方法
公开(公告)号：WO2006091798A3
公开(公告)日：2007-07-12
申请号：PCT/US2006006563
申请日：2006-02-22
申请人： US GOV HEALTH & HUMAN SERV , CATANZARO ANDREW , YARCHOAN ROBERT , BERZOFSKY JAY A , OKAZAKI TAKAHIRO , SNYDER JAMES T II , BRODER SAMUEL
发明人： CATANZARO ANDREW , YARCHOAN ROBERT , BERZOFSKY JAY A , OKAZAKI TAKAHIRO , SNYDER JAMES T II , BRODER SAMUEL
IPC分类号： A61K39/21 , A61K31/00 , A61K39/12 , A61K39/29 , C07K14/02 , C07K14/16 , C07K14/18
CPC分类号： A61K39/00 , A61K2039/57 , C07K14/005 , C12N2710/16722 , C12N2730/10122 , C12N2740/16222 , C12N2770/24222
摘要： The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.
摘要翻译：本发明提供了通过诱导细胞毒性T淋巴细胞（CTL）来识别抗药性病毒的病毒蛋白质内的预定的突变表位来降低对抗病毒药物具有抗性的病毒的病毒载量的方法。通过用包含预定突变的肽免疫宿主诱导CTL。可以通过用于诱导特异性CTL的表位增强来进一步改善免疫刺激肽。由本发明组合物显示并由人HLA限制性CTL介导的抗药性病毒的抗病毒保护尚未获得。

7. 发明申请

WO1998002744A1 DIAGNOSTIC DRUGS FOR AUTOIMMUNE DISEASES 审中-公开
标题翻译：诊断用于自发性疾病的药物
公开(公告)号：WO1998002744A1
公开(公告)日：1998-01-22
申请号：PCT/JP1997001647
申请日：1997-05-15
申请人： KANEKA CORPORATION , OZAKI, Shoichi , SOBAJIMA, Junko , UESUGI, Hiroko , OKAZAKI, Takahiro , TANAKA, Masao , NAKAO, Kazuwa , YOSHIDA, Michiteru , SHIRAKAWA, Hitoshi , OSAKADA, Fumio
发明人： KANEKA CORPORATION
IPC分类号： G01N33/564
CPC分类号： C07K14/4702 , C07K16/00 , C07K16/18 , C07K2317/82 , G01N33/564 , G01N2800/24 , Y10S435/975
摘要： Diagnostic drugs containing at least one substance selected from among polypeptides selected from the HMG-1 family, polypeptides selected from the HMG-2 family and fragments thereof capable of reacting with antibodies of patients with autoimmune diseases; diagnostic kits; and a method for detecting antibodies of patients with autoimmune diseases with the use of the same.
摘要翻译：含有至少一种选自HMG-1家族的多肽，选自HMG-2家族的多肽及其能够与患有自身免疫疾病的患者的抗体反应的片段的物质的诊断药物; 诊断试剂盒; 以及使用其自身免疫性疾病患者的抗体检测方法。

8. 发明专利

JP2003202145A EXHAUST GAS VENTILATING SYSTEM 审中-公开
公开(公告)号：JP2003202145A
公开(公告)日：2003-07-18
申请号：JP2002000188
申请日：2002-01-04
申请人： OKAZAKI TAKAHIRO , DANJO KATSUKO
发明人： OKAZAKI TAKAHIRO , DANJO KATSUKO
IPC分类号： F24F7/00 , A61L9/01 , A61L9/16 , B01D46/00 , B01D47/06 , B01D53/34 , B01D53/38 , B01D53/75 , B01D53/81 , B01J20/22 , F24F7/06
摘要： PROBLEM TO BE SOLVED: To provide an exhaust gas ventilating system that removes oil content and an odor from the air containing oil content and an odor, and discharges the clean air. SOLUTION: The device is made up of a hood, grease filter, water spray device, deodorant filter and an exhaust fan. The air sucked from the hood by the exhaust fan is passed through the grease filter, and is brought into contact with sprayed water from the water spray device on the upper part of the grease filter, preferably by two-stage contact with water, and then, is passed through the deodorant filter to be discharged. A preferable form of the deodorant filter is a packed bed of zeolite carrying metal phthalocyanine derivative. COPYRIGHT: (C)2003,JPO

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式